Rituximab-Induced Esophageal Ulcers and Strictures Presenting as Dysphagia
Abstract
Rituximab is a monoclonal antibody that targets CD20 on B lymphocytes and is approved for the treatment of multiple hematological and autoimmune disorders. Rituximab may cause gastrointestinal side effects such as colitis, diarrhea, and bowel obstruction or perforation. Infusion-related reactions, such as throat irritation, are, however, not linked to any specific esophageal disease. In this study, we report an extremely rare case of rituximab-induced esophageal ulceration and stricture causing progressive, debilitating dysphagia, highlighting the importance of early recognition and prompt management to prevent long-term morbidity.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.